Company details, activities, locations, contacts, financials and reviews for Klaria.
Main company details for Klaria.
Klaria's film adheres to the oral mucosa immediately after application. While the film is attached to the oral mucosa, the drug formulated in the film is transferred directly into the blood, via the oral mucosa. The film remains in place for approximately five minutes and has then completely dissolved.
What does not happen is that the film dissolves in saliva and the drug is therefore swallowed and enters the stomach. These properties make Klaria's technology superior to other transmucosal technologies, which consist of, for example, starch-based films or sprays. These films dissolve quickly and do not adhere to the mucosa, which results in only a part of the active substance passing through the mucosa while the majority is swallowed. These other technologies thus deliver a certain part of the drug transmucosally, while the majority is swallowed and therefore delivered orally.
Our focus is on developing drugs that are not orally available and currently have to be given as an injection. This focus maximizes our value creation and at the same time proves that our technology truly delivers the active substance transmucosally, otherwise our drugs would have no effect. Read more about this in our strategy section.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Klaria on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
